Further to intimation dated January 30, 2023 and pursuant to the provisions of Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) and other applicable provisions, Windlas Biotech has informed that on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on February 08, 2023, approved the appointment of Komal Gupta as the Chief Executive Officer (CEO) and Key Managerial Personnel (KMP) of the Company with effect from February 08, 2023. The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, is given as Annexure I.
The above information is a part of company’s filings submitted to BSE.
